ABSTRACT
With increased longevity and more women becoming centenarians, management of the menopause and postreproductive health is of growing importance as it has the potential to help promote health over several decades. Women have individual needs and the approach needs to be personalised. The position statement provides a short integral guide for all those involved in menopausal health. It covers diagnosis, screening for diseases in later life, treatment and follow-up.
Subject(s)
Menopause , Vagina/pathology , Vulva/pathology , Women's Health , Atrophy/drug therapy , Contraception , Diet , Dyspareunia/drug therapy , Dysuria/drug therapy , Female , Hot Flashes/therapy , Humans , Life Style , Osteoporosis/drug therapy , Perimenopause , SyndromeABSTRACT
OBJECTIVE: The aim of this study was to investigate the effect of a 12-month moderate-to-vigorous exercise program on plantar pressure among postmenopausal women. METHODS: A total of 121 white postmenopausal women participated in a randomized controlled trial (60 women in the exercise group and 61 women in the control group). Women in the exercise group attended training sessions of 60 minutes, 3 days per week, on nonconsecutive days. Weight and basal metabolic rate were evaluated by bioimpedance, and height was evaluated with a stadiometer. Plantar pressure data were collected using the Footscan platform and Software 7.1. RESULTS: After the 1-year intervention, women from the exercise group had (1) lower body mass index, (2) equal basal metabolic rate, (3) lower peak pressures, and (4) lower absolute impulses compared with the women from the control group. Interaction between the exercise group and practice time was found for most of the maximal peak pressure areas (except for metatarsal 4), for all absolute impulse values, and for relative impulses in the hallux, metatarsal 4, midfoot, and medial heel. CONCLUSIONS: This study seems to prove that women who exercise have decreased loading of maximal peak pressures and absolute impulses and, consequently, self-reported pain, soreness, and discomfort in the lower extremity. An interaction effect between group and practice time was found for most of the variables considered, meaning that this 12-month exercise program is effective in the improvement of the biomechanic parameters of plantar pressure.
Subject(s)
Exercise Therapy , Foot/physiology , Postmenopause/physiology , Adult , Aged , Biomechanical Phenomena , Body Mass Index , Female , Humans , Middle Aged , Weight-BearingABSTRACT
During hormone treatments for the relief of the symptoms of postmenopausal women a number of side effects may occur. Some may be due to the wrong choice of the steroids used for treatment or to the route of administration. However, the more important ones deserving much attention are the rare occurrences of malignancies of the uterus and ovaries. The risk for ovarian cancer, if it exists, is minimal and clinically irrelevant. Estrogen only treatments are used only in hysterectomized women. Continuous combined estrogen-progestin treatments have a very low risk of association with endometrial cancers compared with sequential regimens. Tibolone may be associated with a very small risk for endometrial cancers and thus must be properly monitored by transvaginal ultrasound. Breast cancer patients being treated with tamoxifen require careful attention to the endometrium to exclude a carcinoma. For the protection of the endometrium, a progestin-releasing intrauterine devise is an attractive choice. Raloxifene used for a long time to prevent osteoporosis is safe for the endometrium. None of the above-mentioned side effects is enough to prevent a physician from using hormone treatment in postmenopausal women if there are no past or current contraindications.
Subject(s)
Estrogen Replacement Therapy/methods , Ovarian Neoplasms/epidemiology , Uterine Neoplasms/epidemiology , Estrogen Replacement Therapy/adverse effects , Estrogens/adverse effects , Estrogens/therapeutic use , Female , Humans , Norpregnenes/adverse effects , Norpregnenes/therapeutic use , Ovarian Neoplasms/chemically induced , Postmenopause , Progestins/adverse effects , Progestins/therapeutic use , Raloxifene Hydrochloride/adverse effects , Raloxifene Hydrochloride/therapeutic use , Risk Factors , Tamoxifen/adverse effects , Tamoxifen/therapeutic use , Uterine Neoplasms/chemically inducedSubject(s)
Hormones/administration & dosage , Reproduction/physiology , Adrenal Cortex Hormones , Circadian Rhythm , Drug Administration Schedule , Female , Humans , Ovary/drug effects , Ovary/radiation effects , Ovulation Induction/adverse effects , Ovulation Induction/methods , Reproductive Techniques, Assisted , X-RaysSubject(s)
Health Status , International Cooperation , Menopause , Female , Humans , Middle Aged , PortugalABSTRACT
This is a follow-up of a paper ''My dream'' published in Climacteric (2004;7:322-3) in which it was imagined that the WHI investigators would one day apologize to the women of the world for the unjustified damage they has caused with the misinterpretation of the WHI results. Time has shown that this is about to happen as the recent reanalysis of the study show that, contrary to what they had written, HRT does protect from cardiovascular diseases when started in the early postmenopause. Furthermore comments are made about the political background of the reported results as a disservice to the medical community and to the women, themselves.
Subject(s)
Hormone Replacement Therapy , Postmenopause , Women's Health , Female , Humans , PoliticsABSTRACT
In a reanalysis of the Million Women Study (MWS), their authors concluded that prolonged use of hormone replacement therapy (HRT) in postmenopausal women increases the risk of ovarian cancer. Although statistically significant their results are clinically irrelevant, since the attributable risk over 5 years is only 4 per 10 000 HRT users, a figure that is not confirmed by other large studies. This risk is much lower than those associated with obesity, lack of physical exercise, smoking and nulliparity, all of which are preventable. Therefore HRT should continue to be prescribed for symptom relief and improvement of quality of life because the benefits far outweigh the very low potential risks.
Subject(s)
Estrogen Replacement Therapy/adverse effects , Ovarian Neoplasms/epidemiology , Postmenopause/drug effects , Female , Humans , Longitudinal Studies , Odds Ratio , Ovarian Neoplasms/chemically induced , Portugal , RiskABSTRACT
Dormant breast cancer cells are a reality that cannot be overlooked. They may stay dormant either after a spread of cancer cells caused by surgery or after being generated by spontaneous or induced mutations in the course of breast gland growth. Some cases are presented in support of both possibilities, followed by a critical appraisal of the factors that may either keep them dormant or later stimulate their growth into a breast cancer.
Subject(s)
Breast Neoplasms/physiopathology , Neoplasm Metastasis/immunology , Neoplasm Recurrence, Local/immunology , Neoplasms, Second Primary/immunology , Aged , Breast Neoplasms/genetics , Breast Neoplasms/immunology , Breast Neoplasms/surgery , Carcinoma, Intraductal, Noninfiltrating/immunology , Female , Humans , Male , Middle Aged , Neoplasm Metastasis/prevention & control , Neoplasm Recurrence, Local/surgery , Neovascularization, Pathologic/immunologyABSTRACT
Menopausal women should not consider that hormonal treatment is an obligatory long-term commitment. Estrogen-based treatments are extremely effective for vasomotor symptom relief and for vaginal atrophy. HRT also is one of several effective methods for the primary prevention of osteoporosis. If trials were done early after the menopause when the endothelium is likely still to be intact, estrogen-based treatment might be shown to prevent coronary heart disease. However, greater efficacy is to be expected from smoking cessation, proper nutrition, exercise, moderate alcohol consumption, statins, beta-blockers and angiotensin-converting enzyme inhibitors. The treatment options for a menopausal woman should include non-drug-related strategies, non-hormonal pharmaceutical therapies as well as hormonal treatments. The first objective of this contribution is to call to the attention of practising physicians the fact that the Women's Health Initiative (WHI) and Heart and Estrogen/Progestin Replacement Study (HERS) studies involved women much older than the early postmenopausal age groups for whom HRT is prescribed because of symptoms. The second objective is to emphasize that the attending physicians must not only treat the symptomatic women but also prevent the occurrence of diseases more prevalent after 60 years of age. Hormones can safely be used for the former, when not contraindicated, whereas for the latter non-pharmacological interventions and non-hormonal medications are preferable.